Biotech and Pharmaceuticals Life Sciences

  • LONDON/ PARIS, Oct 23- AstraZeneca is plowing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company. Tuesday's agreement is a coup for Innate- run by former AstraZeneca executive Mondher Mahjoubi- which gains rights to sell AstraZeneca's newly...

  • ZURICH, Oct 18- Swiss drugmaker Novartis raised its full-year sales outlook, citing growing revenue from its Cosentyx psoriasis and arthritis drug as well as the performance of its heart failure medicine Entresto, whose third-quarter sales more than doubled. Third-quarter core net income rose 2 percent to $3.1 billion, compared to the average analyst...

  • Oct 18- Biopharmaceutical company Endocyte Inc said on Thursday that Novartis AG will acquire Endocyte in an all-cash deal for $24 per share, or a total equity value of about $2.1 billion. The offer represents a premium of 54 percent to Endocyte's closing price of $15.56 on Oct. 17, Endocyte said. The cancer drug maker expects the transaction to be completed in the...

  • Pharma-focused cloud play Veeva to expand to cosmetics, consumer goods spaces: CEO

    Jim Cramer speaks with Veeva Systems founder and CEO Peter Gassner about his cloud-based software company's huge addressable market.

  • Jim Cramer on "Mad Money."

    Jim Cramer reveals how the Fed's rose-colored glasses could impact your money.

  • BEIJING, Oct 16- A unit of China's vaccine maker Changsheng Bio-technology Co Ltd has been hit with penalties totalling 9.1 billion yuan after it was embroiled in a scandal over falsifying data for a rabies vaccine. China's drug regulator said on Tuesday it had imposed the penalties on the unit Changchun Changsheng Life Sciences Ltd and banned 14 of its...

  • More and more investors are betting that one day, the fish on your plate will come from stem cells grown in bioreactors, instead of the ocean. Scientists say lab-grown fish could reduce overfishing and feed the world's growing demand for seafood.

  • Metastatic cutaneous squamous cell carcinoma is the second-most common form of skin cancer, which accounts for an estimated 7,000 deaths in the United States each year, Sanofi said. Libtayo, which boosts the immune system to fight cancer, will be sold in the United States at a list price of $9,100 for a three-week treatment cycle. Cancer immunotherapy has become...

  • LONDON, Sept 25- AstraZeneca's immunotherapy drug Imfinzi cut the risk of death in patients with mid-stage lung cancer by nearly a third in a closely watched clinical study, reinforcing the case for using the drug in earlier disease. The encouraging overall survival data boost prospects for a medicine that was approved this week in Europe and has already had a...

  • SAN FRANCISCO/ HONG KONG, Sept 24- For three whirlwind days in June, U.S. scientist Zhi Hong went shopping at the Boston Bio Conference to find drugs to fill the pipeline of his two-week-old drug company. Months earlier, Hong had raised $260 million- much of it from Chinese and Asian investors- with a strategy to bring U.S. biotechnology drugs to China, the worlds...

  • BRUSSELS, Aug 22- Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialize one of its experimental drugs which could lead to payments of up to $625 million. Argenx, with bases in the Netherlands and Belgium, has several drugs to treat autoimmune diseases and cancer in various stages of medical...

  • Ken Richards of Leaf Resources discusses how his company makes money by "maximizing the waste" from plants.

  • Sealed boxes of freeze-dried rabies vaccines for human use produced by Changchun Changsheng Bio-tech on July 23, 2018.

    China said on Saturday it has sacked six senior officials at its food and drug regulator after a safety scandal.

  • SHANGHAI, Aug 18- China said on Saturday it has sacked six senior officials at its food and drug regulator after a safety scandal at vaccine maker Changsheng Biotechnology Co Ltd revealed failings at the government body including inadequate supervision. In a posting on its website, the State Administration for Market Regulation said that among officials...

  • Medtronic pacemakers may be at risk from hackers

    Security researchers have discovered multiple security flaws that could allow a malicious hacker to tamper with a Medtronic pacemaker.

  • SHANGHAI, Aug 17- Shares in China fell on Friday, pulled down by healthcare companies after a vaccine maker warned it could be delisted due to an ongoing vaccine scandal, but planned talks between the United States and China helped ease trade war fears. **China sacked a senior provincial official and is probing a former top drug regulator after a safety scandal at...

  • *Meeting headed by China's president orders sackings. BEIJING, Aug 17- China has sacked a senior provincial official and is probing a former top drug regulator after a safety scandal at vaccine maker Changsheng Biotechnology Co Ltd, which again warned it could be delisted over the scandal. A meeting of the ruling Communist Party's Politburo, overseen by...

  • FRANKFURT, Aug 16- Pfizer has agreed to pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach. Privately-held BioNTech will receive $120 million upfront plus up to $305 million depending on certain development...

  • Analysts project those drugs could top $1 million to $1.5 million in price. Rather than rail against the drugs expected high prices, Miller echoes the familiar drug company argument that the potentially curative therapies will likely be worth the high cost if they supplant the hundreds of thousands of dollars in annual medical costs to treat ailments such as...

  • Analysts project those drugs could top $1 million to $1.5 million in price. Rather than rail against the drugs expected high prices, Miller echoes the familiar drug company argument that the potentially curative therapies will likely be worth the high cost if they supplant the hundreds of thousands of dollars in annual medical costs to treat ailments such as...